Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Indutrade AB ( (SE:INDT) ).
Indutrade AB has expanded its Life Science business area with the acquisition of Axotan AB, a Swedish technical trading company specialising in stoma bags, stoma accessories and wound care products. Axotan, founded in 1991 and based in Helsingborg, serves pharmacies and healthcare providers across Sweden and generates annual sales of about SEK 50 million.
The deal, completed today, marks Indutrade’s third acquisition in 2026 and is expected to have a marginally positive effect on earnings per share. The transaction underscores Indutrade’s strategy of adding niche, health-related technical product distributors to strengthen its position in the Nordic medical supplies market and support continued profitable growth.
The most recent analyst rating on (SE:INDT) stock is a Buy with a SEK245.00 price target. To see the full list of analyst forecasts on Indutrade AB stock, see the SE:INDT Stock Forecast page.
More about Indutrade AB
Indutrade AB is an international technology and industrial business group comprising over 220 companies across some 30 countries, mainly in Europe. The group focuses on developing, manufacturing and selling technically advanced components, systems and services in selected niches, pursuing a decentralised, acquisition-driven growth strategy. Its shares are listed on Nasdaq Stockholm and it generated SEK 32.2 billion in net sales in 2025.
Average Trading Volume: 426,879
Technical Sentiment Signal: Hold
Current Market Cap: SEK80.88B
For a thorough assessment of INDT stock, go to TipRanks’ Stock Analysis page.